{"groups":[{"description":"Patients receive Epoetin alfa 40,000 units subcutaneously every week for 15 weeks (15 doses)","id":"FG000","title":"Epoetin Alfa - 40k Weekly"},{"description":"Patients receive Epoetin alfa 80,000 units subcutaneously every 3 weeks for 15 weeks (5 doses)","id":"FG001","title":"Epoetin Alfa - 80k Every 3 Weeks"},{"description":"Patients receive Epoetin alfa 120,000 units subcutaneously every 3 weeks for 15 weeks (5 doses)","id":"FG002","title":"Epoetin Alfa - 120k Every 3 Weeks"},{"description":"Patients receive Darbepoetin alfa 500 micrograms (mcg) subcutaneously every 3 weeks for 15 weeks (5 doses)","id":"FG003","title":"Darbepoetin Alfa - 500 mcg Every 3 Weeks"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"6"},{"groupId":"FG002","numSubjects":"4"},{"groupId":"FG003","numSubjects":"9"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"4"},{"groupId":"FG001","numSubjects":"7"},{"groupId":"FG002","numSubjects":"7"},{"groupId":"FG003","numSubjects":"1"}],"type":"Death"},{"reasons":[{"groupId":"FG000","numSubjects":"8"},{"groupId":"FG001","numSubjects":"3"},{"groupId":"FG002","numSubjects":"2"},{"groupId":"FG003","numSubjects":"2"}],"type":"Adverse Event"},{"reasons":[{"groupId":"FG000","numSubjects":"8"},{"groupId":"FG001","numSubjects":"11"},{"groupId":"FG002","numSubjects":"5"},{"groupId":"FG003","numSubjects":"5"}],"type":"Other"},{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"}],"type":"Cancel"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"61"},{"groupId":"FG001","numSubjects":"60"},{"groupId":"FG002","numSubjects":"58"},{"groupId":"FG003","numSubjects":"57"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"39"},{"groupId":"FG001","numSubjects":"33"},{"groupId":"FG002","numSubjects":"40"},{"groupId":"FG003","numSubjects":"40"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"22"},{"groupId":"FG001","numSubjects":"27"},{"groupId":"FG002","numSubjects":"18"},{"groupId":"FG003","numSubjects":"17"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"There were two canceled participants and 1 ineligible participants prior to study medication begins. These three participants were excluded from all analysis.","recruitmentDetails":"Two hundred and thirty-nine (239) participants were enrolled at 10 Mayo Clinic Cancer Research Consortium (MCCRC) sites between February 2007 and December 2008."}